How have CRBP shares performed this year?

Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 861.3% and is now trading at $58.06. View the best growth stocks for 2024 here .

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.26.

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (2.23%) and Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Yuval Cohen , Sean F Moran and Craig Stuart Millian. View institutional ownership trends .

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V) , HP (HPQ) , Fortive (FTV) , Lowe's Companies (LOW) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) and Matinas BioPharma (MTNB) .

NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$58.06

+2.61 (+4.71%)

(As of 07/26/2024 ET)

Compare

Today's Range: $56.22
▼
$59.72
50-Day Range: $41.38
▼
$60.28
52-Week Range: $3.03
▼
$61.18

Volume: 227,884 shs
Average Volume: 559,201 shs
Market Capitalization: $620.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.60

Get Corbus Pharmaceuticals alerts:

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 28.5% Upside
$74.60 Price Target
Short Interest: Bearish
11.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.81
Based on 19 Articles This Week
Insider Trading: Selling Shares
$2.53 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.05) to ($4.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.26 out of 5 stars

Medical Sector

157th out of 936 stocks

Pharmaceutical Preparations Industry

64th out of 436 stocks

3.5

Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Corbus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.
Read more about Corbus Pharmaceuticals' stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
11.25% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently increased by 41.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

3.8

News and Social Media Coverage

News Sentiment
Corbus Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for Corbus Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
17 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.
MarketBeat Follows
9 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,530,799.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Corbus Pharmaceuticals' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($5.05) to ($4.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -8.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -8.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Read more about Corbus Pharmaceuticals' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRBP Stock News Headlines

July 25 at 8:00 AM | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Lowered to Sell at StockNews.com

July 25 at 2:48 AM | americanbankingnews.com

Corbus Pharmaceuticals Holdings, Inc. Expected to Earn FY2024 Earnings of ($4.86) Per Share (NASDAQ:CRBP)

July 27, 2024 | Crypto Swap Profits (Ad)

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

July 25 at 1:21 AM | americanbankingnews.com

Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Price Target at $73.25

July 24 at 1:37 AM | americanbankingnews.com

Equities Analysts Offer Predictions for Corbus Pharmaceuticals Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:CRBP)

July 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Corbus Pharmaceuticals’ Promising Drug Pipeline and Growth Potential

July 22, 2024 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Buy Rating from HC Wainwright

July 21, 2024 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Up 3.1%

July 27, 2024 | Crypto Swap Profits (Ad)

625,000% Gain

June 30, 2024 | investorplace.com

Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet

June 3, 2024 | seekingalpha.com

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

June 1, 2024 | globenewswire.com

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024 | globenewswire.com

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024 | globenewswire.com

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 13, 2024 | msn.com

RBC Capital Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation

May 9, 2024 | globenewswire.com

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024 | seekingalpha.com

CRBP Corbus Pharmaceuticals Holdings, Inc.

May 7, 2024 | investorplace.com

CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024

See More Headlines

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/07/2024
Today: 7/26/2024
Next Earnings (Estimated): 8/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceutical Products
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 40
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $74.60
High Stock Price Target: $85.00
Low Stock Price Target: $46.00
Potential Upside/Downside: +28.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -135.17%
Return on Assets: -57.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.69
Quick Ratio: 4.69

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 705.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.56) per share
Price / Book: -37.22

Miscellaneous

Outstanding Shares: 10,690,000
Free Float: 10,260,000
Market Cap: $620.66 million
Optionable: Optionable
Beta: 2.59

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

Dr. Yuval Cohen Ph.D. (Age 49)
CEO & Director
Comp: $907.78k
Mr. Sean F. Moran CPA (Age 66)
M.B.A., Chief Financial Officer
Comp: $609.28k
Ms. Lindsey Smith
Head of Corporate Communications & Patient Advocacy
Ms. Christina Bertsch
Head of Human Resources
Dr. Dominic Smethurst M.A. (Age 49)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRBP Stock Analysis - Frequently Asked Questions

How have CRBP shares performed this year?: Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 861.3% and is now trading at $58.06.
View the best growth stocks for 2024 here.
How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.26.
Who are Corbus Pharmaceuticals' major shareholders?: Corbus Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (2.23%) and Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian.
View institutional ownership trends.
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Matinas BioPharma (MTNB).

This page (NASDAQ:CRBP) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions